Vitamin D Analogues

Secondary HPTmedium

A CKD stage 5 dialysis patient has PTH of 650 pg/mL with serum calcium 9.6 mg/dL and phosphorus 4.2 mg/dL. Which statement best describes the choice between calcitriol and paricalcitol for secondary HPT management?

  1. A.Calcitriol and paricalcitol have identical effects on calcium and phosphorus absorption.
  2. B.Paricalcitol reduces PTH with less effect on calcium and phosphorus levels than calcitriol.Correct
  3. C.Calcitriol is preferred in dialysis patients because it is more potent at suppressing PTH.
  4. D.Paricalcitol is contraindicated when phosphorus is >4.0 mg/dL.

Explanation

Paricalcitol (19-nor-1,25-(OH)2D2) is a selective vitamin D receptor activator (SVDRA) with preferential activity at parathyroid gland VDR over intestinal VDR. This results in effective PTH suppression with less intestinal calcium and phosphorus absorption compared to calcitriol, reducing the risk of hypercalcemia and hyperphosphatemia. Observational data suggest paricalcitol may be associated with improved survival versus calcitriol in dialysis patients, though randomized data are limited.

Why each option

A.
Incorrect. Paricalcitol has relatively less intestinal calcium/phosphorus absorption effect than calcitriol.
B.
Correct. Paricalcitol: selective SVDRA, ↑ parathyroid selectivity, ↓ intestinal Ca/P absorption vs calcitriol.
C.
Incorrect. Calcitriol is not preferred in dialysis; paricalcitol has a better side effect profile for Ca/P management.
D.
Incorrect. Phosphorus >4.0 mg/dL is not a specific contraindication to paricalcitol; however, hyperphosphatemia warrants caution with all vitamin D analogues.

Reference: KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD; key trials and related guideline evidence (EVOLVE, ADVANCE, DCOR, etelcalcetide/cinacalcet comparative studies)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

Browse other topics